目的探讨RNA结合基序蛋白3(RNA-binding motif protein 3,RBM3)在结直肠癌(colorectal cancer,CRC)中的表达及其与临床病理学特征、预后的关系。方法收集上海市杨浦区控江医院病理科存档的CRC组织150例及肠镜活检正常结直肠黏膜组织46...目的探讨RNA结合基序蛋白3(RNA-binding motif protein 3,RBM3)在结直肠癌(colorectal cancer,CRC)中的表达及其与临床病理学特征、预后的关系。方法收集上海市杨浦区控江医院病理科存档的CRC组织150例及肠镜活检正常结直肠黏膜组织46例。采用免疫组化SP法检测RBM3蛋白表达,采用χ^2检验和Kaplan-Meier法比较RBM3不同表达的临床病理特征和生存率的差异。结果CRC组织中RBM3高表达率为34.0%,显著低于正常结直肠黏膜组织(69.6%)(χ^2=18.239,P<0.001)。RBM3高表达与肿瘤浸润深度、淋巴结转移、远处转移和TNM分期均呈负相关(P均<0.05)。RBM3高表达者生存率显著高于低表达者(χ^2=4.128,P=0.042)。结论RBM3高表达与CRC发生、发展中的不良事件如肿瘤浸润、远处转移等呈负相关,且与术后良好预后有关。RBM3有望成为CRC诊断和预后的生物学标志物。展开更多
Background The RNA-binding motif protein 3 （RBM3）, which is transcriptionally induced by low temperature and hypoxia, has recently been found to be upregulated in human tumors. However, its expression status in huma...Background The RNA-binding motif protein 3 （RBM3）, which is transcriptionally induced by low temperature and hypoxia, has recently been found to be upregulated in human tumors. However, its expression status in human astrocytoma is not well defined. This article focuses on the differential expression of RBM3 in human astrecytomas of different grades and normal brain tissues. Methods RBM3 was detected in astrocytomas and normal brain tissues by quantitative real-time PCR, immunohistochemistry, and Western blotting. Analysis of variance was performed on the data from quantitative real-time PCR. The Fisher＇s exact test was used to analyze the immunohistochemistry results. A P-value of less than 0.05 indicates a statistically significant difference. Results On one hand, the mRNA expression levels of three X-chromosome-related RBM genes （RBMX, RBM3, and RBM10） were detected by quantitative real-time PCR. The results showed that there were no significant differences in RBMX and RBM10 mRNA expression levels in human astrocytomas of different grades and normal brain tissues. However, RBM3 mRNA expression levels were elevated in high-grade （World Health Organization （WHO） Grade Ill- IV） astrocytomas versus low-grade （WHO Grade I-II） astrocytomas （5.06±0.66 vs. 1.60±0.58; P 〈0.05） or normal controls （5.06±0.66 vs. 1.03±0.22; P 〈0.05） as determined by quantitative real-time PCR analysis. On the other hand, immunohistochemistry showed an increased RBM3 labeling index in astrocytomas of different grades and normal brain tissues （positive staining rate： astrocytoma Grade IV, 92.9%; astrocytoma Grade III, 81.8%; astrocytoma Grade I-II, 50%; normal brain tissues, 37.5%; high-grade astrocytoma versus normal brain tissues, P 〈0.05; high-grade astrecytoma versus low-grade astrocytoma, P 〈0.05）. The higher protein levels of RBM3 were also validated in high-grade astrocytomas and low-grade astrocytomas compared with normal brain tissues by Western blotting. Conclusions These data suggest that the overexpression of RBM3 may serve as an important molecular mechanism underlying astrocytic carcinogenesis. Moreover, RBM3 may have proliferative and/or preto-oncogenic functions in human astrecytomas.展开更多
文摘目的探讨RNA结合基序蛋白3(RNA-binding motif protein 3,RBM3)在结直肠癌(colorectal cancer,CRC)中的表达及其与临床病理学特征、预后的关系。方法收集上海市杨浦区控江医院病理科存档的CRC组织150例及肠镜活检正常结直肠黏膜组织46例。采用免疫组化SP法检测RBM3蛋白表达,采用χ^2检验和Kaplan-Meier法比较RBM3不同表达的临床病理特征和生存率的差异。结果CRC组织中RBM3高表达率为34.0%,显著低于正常结直肠黏膜组织(69.6%)(χ^2=18.239,P<0.001)。RBM3高表达与肿瘤浸润深度、淋巴结转移、远处转移和TNM分期均呈负相关(P均<0.05)。RBM3高表达者生存率显著高于低表达者(χ^2=4.128,P=0.042)。结论RBM3高表达与CRC发生、发展中的不良事件如肿瘤浸润、远处转移等呈负相关,且与术后良好预后有关。RBM3有望成为CRC诊断和预后的生物学标志物。
文摘Background The RNA-binding motif protein 3 （RBM3）, which is transcriptionally induced by low temperature and hypoxia, has recently been found to be upregulated in human tumors. However, its expression status in human astrocytoma is not well defined. This article focuses on the differential expression of RBM3 in human astrecytomas of different grades and normal brain tissues. Methods RBM3 was detected in astrocytomas and normal brain tissues by quantitative real-time PCR, immunohistochemistry, and Western blotting. Analysis of variance was performed on the data from quantitative real-time PCR. The Fisher＇s exact test was used to analyze the immunohistochemistry results. A P-value of less than 0.05 indicates a statistically significant difference. Results On one hand, the mRNA expression levels of three X-chromosome-related RBM genes （RBMX, RBM3, and RBM10） were detected by quantitative real-time PCR. The results showed that there were no significant differences in RBMX and RBM10 mRNA expression levels in human astrocytomas of different grades and normal brain tissues. However, RBM3 mRNA expression levels were elevated in high-grade （World Health Organization （WHO） Grade Ill- IV） astrocytomas versus low-grade （WHO Grade I-II） astrocytomas （5.06±0.66 vs. 1.60±0.58; P 〈0.05） or normal controls （5.06±0.66 vs. 1.03±0.22; P 〈0.05） as determined by quantitative real-time PCR analysis. On the other hand, immunohistochemistry showed an increased RBM3 labeling index in astrocytomas of different grades and normal brain tissues （positive staining rate： astrocytoma Grade IV, 92.9%; astrocytoma Grade III, 81.8%; astrocytoma Grade I-II, 50%; normal brain tissues, 37.5%; high-grade astrocytoma versus normal brain tissues, P 〈0.05; high-grade astrecytoma versus low-grade astrocytoma, P 〈0.05）. The higher protein levels of RBM3 were also validated in high-grade astrocytomas and low-grade astrocytomas compared with normal brain tissues by Western blotting. Conclusions These data suggest that the overexpression of RBM3 may serve as an important molecular mechanism underlying astrocytic carcinogenesis. Moreover, RBM3 may have proliferative and/or preto-oncogenic functions in human astrecytomas.
